What is MOTS-c and why does its sequence matter for verification?
MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome. It was characterised as a short peptide involved in cellular metabolic signalling and has been studied extensively in cell and animal models (PMID:25738459; PMID:27216708). Later work reported that MOTS-c can translocate to the nucleus under metabolic stress to influence gene expression (PMID:29983246), and reviews have catalogued its proposed mechanisms across metabolism, stress and ageing research contexts (PMID:36670507; PMID:36761202). For a buyer, the relevant point is structural, not biological: MOTS-c is a defined, low-molecular-weight peptide of 16 amino acid residues. That fixed composition means its theoretical monoisotopic and average masses can be calculated from the published sequence and then matched against experimental data on a supplier's CoA. A defined sequence also permits fragment-level confirmation by tandem mass spectrometry. Because MOTS-c is short relative to recombinant proteins, it is typically produced by solid-phase peptide synthesis, which introduces characteristic synthesis-related impurities (deletion, truncation and oxidised species) that competent analytical documentation should resolve and quantify. Understanding the peptide as a well-defined chemical entity — rather than an undefined 'blend' — is what makes independent verification possible. When evaluating an Australian source, the first question is simply whether the listing corresponds to a single, correctly specified 16-residue sequence with a stated molecular formula and net peptide content, all framed strictly for laboratory research use.
How is MOTS-c identity confirmed by mass spectrometry?
Mass spectrometry is the primary tool for confirming that a vial labelled MOTS-c actually contains the intended sequence. Two complementary readouts should appear in a thorough batch report. First, an intact-mass measurement by electrospray ionisation (ESI-MS) or MALDI-TOF establishes that the observed molecular weight matches the theoretical mass calculated from the MOTS-c sequence within the method's stated tolerance. A single dominant, correctly charged species indicates the bulk material is the expected peptide; unexpected mass shifts of +16 Da suggest oxidation, while losses corresponding to whole residues suggest deletion sequences. Second, and more definitive, tandem mass spectrometry (MS/MS) fragments the peptide and maps the resulting b- and y-ions back to the amino-acid sequence, confirming not just the correct mass but the correct order of residues. This distinguishes MOTS-c from an isobaric peptide that happens to share the same total mass. A credible report specifies the instrument, ionisation mode, calibration reference and the acceptance tolerance (commonly expressed in Da or ppm). Orthogonality matters: pairing HPLC retention behaviour with an independent MS measurement reduces the chance that a co-eluting contaminant is mistaken for the target. Where a supplier provides only a purity percentage with no identity method, the material's identity is effectively unverified. For MOTS-c specifically, ask whether the CoA reports both an intact mass and a sequence-confirming MS/MS or amino-acid analysis result, and whether the theoretical mass quoted is consistent with the published 16-residue sequence. Identity confirmation is an analytical statement about the molecule only — it carries no implication about biological activity or suitability for any use beyond research.
What HPLC purity data should a MOTS-c CoA show?
Purity for a synthetic peptide such as MOTS-c is conventionally reported as chromatographic purity by reversed-phase HPLC (RP-HPLC), typically with UV detection at 214 nm where the peptide backbone absorbs. A meaningful CoA states the percentage of the main peak relative to total integrated peak area, the gradient and mobile-phase composition, the column chemistry (commonly C18), the detection wavelength and the run time. Purity figures are only interpretable alongside these parameters, because integration thresholds and gradient steepness materially affect the reported number. Beyond the headline percentage, look for an impurity or related-substances profile: closely eluting deletion and truncation peaks, and oxidised variants, are the impurities most relevant to a synthetic peptide of this length. A responsible report characterises the largest individual impurity rather than lumping everything into a single 'other' figure. Peak-purity assessment using a diode-array detector (peak-purity or purity-angle analysis) adds confidence that the main peak represents a single component rather than co-eluting species, and system-suitability data (resolution, tailing factor, replicate injection precision) demonstrates the method was performing correctly on the day of testing. When comparing Australian listings, treat purity numbers quoted without a method as unverifiable claims. A batch-specific chromatogram — not a generic representative trace — is the standard to insist on, because it ties the number to the actual lot in the vial. Reversed-phase purity, intact mass and sequence confirmation together form the analytical backbone of a defensible MOTS-c characterisation package, all reported for research use only.
Why do counterion and water content appear on a MOTS-c report?
Two quantitative attributes are frequently overlooked but directly affect how much actual peptide is in a vial: counterion content and residual water. Synthetic peptides are commonly isolated as salts, most often trifluoroacetate (TFA) or acetate, depending on the purification and any counterion-exchange step. The counterion contributes mass that is not peptide, so a vial nominally labelled by gross weight can contain substantially less MOTS-c than the label implies once salt and water are subtracted. This is why net peptide content — the salt-corrected, moisture-corrected mass of actual peptide — is a more honest quantitative figure than gross fill weight. Counterion identity and level are determined by ion chromatography or related methods, and residual water is measured by Karl Fischer titration. Both should be stated on a complete CoA. For laboratories preparing solutions for in-vitro research, knowing net peptide content is essential for accurate concentration calculations; without it, reported concentrations are only nominal. Water content also has a stability dimension: residual moisture in a lyophilised peptide can promote hydrolytic and oxidative degradation over time, so a low, documented water figure supports the integrity of the material as supplied. When evaluating an Australian supplier, check whether the documentation reports the counterion form, its percentage, the Karl Fischer water result and a derived net peptide content. A report that provides only a purity percentage, with no counterion or moisture data, gives an incomplete picture of what is physically present in the vial. These are compositional, quantitative measurements — they describe the material, not any intended effect.
What batch traceability and documentation should an Australian supplier provide?
Analytical numbers are only trustworthy if they are tied to the specific lot you receive, which is where traceability documentation matters. A complete package links a unique batch or lot number across the CoA, the chromatograms, the mass spectra and the vial label, so the data can be cross-referenced to the physical product. Look for lot-release documentation that states the specification limits applied, the date of testing, the analytical methods used and, ideally, provision for independent confirmation by orthogonal methods. For a peptide such as MOTS-c, which appears across a broad research literature spanning metabolic, cardiovascular and ageing models (PMID:34798268; PMID:34859377; PMID:36156853; PMID:36233287), reproducible research depends on knowing that the material tested in one experiment matches the next lot ordered — batch-to-batch consistency documentation supports this. An Australian advantage is local stock held domestically with tracked dispatch and batch paperwork supplied per order, which shortens transit and keeps the documentation trail intact. Practical questions to ask a supplier: is a batch-specific CoA provided (not a generic template)? Are the chromatograms and mass spectra from the actual lot? Is there a stated shelf-life or retest date with storage guidance? Can the lot number on the vial be matched to the documentation? Is the material clearly designated for research use only? A vendor that can answer these questions with lot-specific evidence demonstrates the quality-systems maturity that distinguishes a research supplier from an anonymous reseller. None of this documentation asserts any therapeutic property; it establishes only the identity, purity, composition and traceability of a chemical intended for laboratory research.
How should buyers interpret the MOTS-c research literature responsibly?
The published MOTS-c literature is substantial and expanding, and it is worth understanding what that body of work does and does not tell a buyer. Foundational papers described MOTS-c as a mitochondrial-derived peptide studied in metabolic contexts (PMID:25738459; PMID:27216708), and later mechanistic work reported nuclear translocation under metabolic stress (PMID:29983246) alongside regulation of plasma metabolites in animal models (PMID:31293078). Other studies have examined MOTS-c in thermogenesis and cold-adaptation models (PMID:31109005) and in cardiac and oxidative-stress cell models (PMID:34859377; PMID:36156853), while reviews summarise its proposed roles in stress, metabolism and ageing (PMID:36233287; PMID:36670507; PMID:36761202). Importantly, at least one report has raised context-dependent findings around senescence (PMID:30058454), underscoring that mechanistic outcomes vary with model system and are not settled. For a research buyer, the key interpretive discipline is this: these are pre-clinical and mechanistic studies in cells and animals, not evidence of any human benefit, and they do not constitute guidance for use. The literature's practical value to a purchaser is that it defines MOTS-c as a well-characterised, sequence-defined peptide — which is exactly what makes the analytical verification steps above possible and meaningful. Cite primary sources rather than vendor summaries, note the model system for any finding, and treat any listing that markets outcomes rather than documenting composition as a compliance and quality red flag. Sound procurement rests on verifiable analytical documentation, not on claims drawn selectively from the research record.
Order Mots C with documentation
If this guide helped you evaluate Mots C for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Mots C card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What documentation should come with research-grade MOTS-c in Australia?
Expect a batch-specific certificate of analysis covering identity by mass spectrometry (intact mass plus sequence confirmation), RP-HPLC purity with stated method parameters, counterion identity and level, Karl Fischer water content, net peptide content, and a lot number that cross-references the chromatograms, spectra and vial label — all for research use only.
How is MOTS-c identity confirmed analytically?
Identity is confirmed by matching the measured intact mass (ESI-MS or MALDI-TOF) to the theoretical mass of the 16-residue sequence, then verifying the residue order by tandem MS/MS fragment mapping. Pairing an independent HPLC method with mass spectrometry provides orthogonal confirmation and reduces the chance of a co-eluting contaminant being misread as the target peptide.
Why does net peptide content matter more than vial weight?
Peptides are usually supplied as salts (often acetate or TFA) and contain residual water, both of which add mass that is not peptide. Net peptide content is the salt-corrected, moisture-corrected mass of actual MOTS-c, so it gives a truer basis for calculating solution concentrations in in-vitro research than gross fill weight.
What HPLC details make a purity figure meaningful?
A purity percentage is only interpretable with its method: column chemistry, gradient, mobile phase, detection wavelength (commonly 214 nm), integration threshold and system-suitability data. A batch-specific chromatogram and a characterised largest-impurity figure are far more informative than a bare percentage quoted without any supporting method.
Does the MOTS-c research literature support any human use?
No. The published studies are pre-clinical and mechanistic work in cell and animal models. They characterise MOTS-c as a defined mitochondrial-derived peptide but do not establish any human benefit and are not guidance for use. Material sold on this basis is strictly for laboratory research use only.
References
- PMID:25738459 — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Cell Metab — 2015
- PMID:27216708 — MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism — Free Radic Biol Med — 2016
- PMID:29983246 — The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress — Cell Metab — 2018
- PMID:31293078 — The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity — Physiol Rep — 2019
- PMID:31109005 — Mitochondrial-Derived Peptide MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation — Int J Mol Sci — 2019
- PMID:34859377 — The Mitochondrial-Derived Peptide MOTS-c Attenuates Oxidative Stress Injury and the Inflammatory Response of H9c2 Cells Through the Nrf2/ARE and NF-κB Pathways — Cardiovasc Eng Technol — 2022
- PMID:36156853 — Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice — J Cell Mol Med — 2022
- PMID:36233287 — MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases — Int J Mol Sci — 2022
- PMID:36670507 — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging — J Transl Med — 2023
- PMID:36761202 — MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne) — 2023
- PMID:34798268 — The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus — Pharmacol Res — 2022
- PMID:30058454 — Mitochondrial-Derived Peptides Exacerbate Senescence — Rejuvenation Res — 2018
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
